Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 3/20 | 0.49 |
| ▸ | PRCP | P42785 | 9/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12567724 | 1.00 | HPGDS (0.49) | HPGDSPRCPCYP3A4CYP2C9NR1I2 | |
| SCHEMBL10214293 | 0.96 | PRCP (0.49) | HPGDSPRCPCYP3A4CYP2C9NR1I2 | |
| SCHEMBL10170848 | 0.95 | HPGDS (0.49) | HPGDSPRCPCYP3A4CYP2C9NR1I2 | |
| SCHEMBL10170877 | 0.92 | PRCP (0.46) | HPGDSPRCPCYP3A4CYP2C9NR1I2 | |
| SCHEMBL10170910 | 0.92 | HPGDS (0.46) | HPGDSPRCPCYP3A4CYP2C9NR1I2 | |
| SCHEMBL10217732 | 0.88 | PRCP (0.51) | HPGDSPRCPCYP3A4CYP2C9NR1I2 | |
| SCHEMBL10216761 | 0.87 | PRCP (0.48) | HPGDSPRCPCYP3A4CYP2C9NR1I2 | |
| SCHEMBL12599418 | 0.87 | PRCP (0.51) | HPGDSPRCPCYP3A4CYP2C9NR1I2 | |
| SCHEMBL10177193 | 0.87 | HPGDS (0.57) | HPGDSPRCPCYP3A4CYP2C9NR1I2 | |
| SCHEMBL2707710 | 0.86 | PRCP (0.51) | HPGDSPRCPCYP3A4CYP2C9NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150554-B2 | Fused ring inhibitors of hepatitis C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20120040962-A1 | FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110152246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, IRF3 | HPGDS 3219/4885PRCP 1157/4885CYP3A4 1292/4885 |
| US-20120040962-A1 | FUSED RING INHIBITORS OF HEPATITIS C | HAVCR2, HCCS, ZC3HAV1 | HPGDS 1159/4885PRCP 157/4885CYP3A4 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.